文献速递血栓与止血

达比加群治疗急性静脉血栓栓塞的女性异常子宫出血少于华法林

Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2018-08-11

该研究为RE-COVER合并研究与RE-MEDY试验的事后分析,纳入1280例18-50岁女性急性静脉血栓栓塞患者,比较达比加群与华法林治疗期间异常子宫出血(AUB)的发生率。达比加群组AUB发生率为5.9%,华法林组为9.6%,OR为0.59(95%CI 0.39-0.90;P=0.015)。

要点

  • 达比加群组AUB发生率5.9%,华法林组9.6%,OR 0.59(95%CI 0.39-0.90;P=0.015)。
  • 达比加群组大出血3例(0.5%),华法林组5例(0.8%),HR 0.65(95%CI 0.15-2.72)。
  • 达比加群组大出血或非大出血相关出血30例(4.7%),华法林组57例(8.9%),HR 0.53(95%CI 0.34-0.83)。

核心结论

  • 达比加群治疗与华法林相比,AUB风险显著降低41%。
  • 作者认为未来需要在日常实践中开展研究以 corroborate 这些发现。

研究设计与样本

  • RE-COVER合并研究与RE-MEDY试验的事后分析。
  • 共纳入1280例18-50岁女性急性静脉血栓栓塞患者,达比加群组643例,华法林组637例。

主要发现

  • 总体AUB发生率为8.1%,达比加群组为5.9%,华法林组为9.6%,OR为0.59(95%CI 0.39-0.90;P=0.015)。
  • 达比加群组大出血3例(0.5%),华法林组5例(0.8%),HR为0.65(95%CI 0.15-2.72)。
  • 达比加群组大出血或非大出血相关出血30例(4.7%),华法林组57例(8.9%),HR为0.53(95%CI 0.34-0.83)。
  • 无致死性出血事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出未来需要在日常实践中开展研究以 corroborate 这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Factor Xa inhibitors cause more abnormal menstrual bleeding (AUB) than vitamin-K antagonists (VKA). We analyzed data of AUB in women, evaluating dabigatran versus VKA. We observed a 41% lower risk of AUB in women on dabigatran compared to those on VKA. Our findings of lower AUB risk on dabigatran should be corroborated in future studies. SUMMARY: Introduction Although direct oral anticoagulants (DOACs) are associated with a better safety profile than warfarin in patients with acute venous thromboembolism (VTE), direct factor Xa inhibitors involve a higher risk of abnormal uterine bleeding (AUB). We aimed to determine the risk of AUB during anticoagulation with dabigatran compared with warfarin. Methods Post-hoc analysis of the pooled RE-COVER studies and the RE-MEDY trial. Incidences of AUB, based on a defined preferred terms search for adverse events, in female patients aged 18-50 years treated with dabigatran, were compared with those in women treated with warfarin. Results Of the 2964 women included in the above-mentioned trials, 1280 women were in the relevant age category (18-50 years) and included in the current analysis. A total of 643 patients were randomized to treatment with dabigatran and 637 to treatment with warfarin. The overall rate of AUB was 8.1%, 5.9% for the women treated with dabigatran and 9.6% in those treated with warfarin, for an odds ratio for dabigatran-treated patients of 0.59 (95% confidence interval [CI], 0.39-0.90; P = 0.015). In the dabigatran-treated patients, three (0.5%) suffered major bleeding (MB) vs. five (0.8%) in the warfarin-treated patients (HR, 0.65; 95% CI, 0.15-2.72). MB or non-major relevant bleeding occurred in 30 (4.7%) patients randomized to receive dabigatran and 57 (8.9%) randomized to receive warfarin (HR, 0.53; 95% CI, 0.34-0.83). None of the bleeding events was fatal. Conclusion Dabigatran treatment was associated with a significantly (41%) lower risk of AUB than warfarin. Future studies in daily practice are needed to corroborate these findings.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Huisman MV, Ferreira M, Feuring M, et al. Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism. J Thromb Haemost. 2018. PMID: 29974611. doi:10.1111/jth.14226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。